Search Medical Condition
Please enter condition
Please choose location
 

Shelby, North Carolina Clinical Trials

A listing of Shelby, North Carolina clinical trials actively recruiting patient volunteers.

RESULTS

Found (13) clinical trials

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer.

Patients will be randomised in 1:1 ratio to either olaparib or placebo. Randomisation will be stratified by Hormone receptor status (ER and/or PgR positive/HER2 negative versus TNBC), prior neoadjuvant versus adjuvant chemotherapy and prior platinum use for breast cancer. Randomised patients will receive study treatment for up to a maximum ...

Phase

0.0 miles

Learn More »

PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Collected data will be compared to historic data of the same participant in case-crossover design.

Phase

0.0 miles

Learn More »

S1216 Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.

Phase

0.0 miles

Learn More »

A Phase III Parallel Group Study Comparing the Efficacy Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA® dry powder inhaler (DPI) is being developed by GlaxoSmithKline (GSK) with the aim of providing a new treatment option for the management of asthma by improving lung function, health-related quality of life (HRQoL) and symptom control over established ...

Phase

0.0 miles

Learn More »

Study of VIS410 in Subjects With Uncomplicated Influenza A

Subjects will be admitted to an infusion unit for drug administration and observation following infusion. The study is designed to compare an infusion of a single high or low IV dose of VIS410 against placebo. Subjects will be followed for 100 (±7 days).

Phase

0.0 miles

Learn More »

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis

Patients will be randomized to treatment at their first gout flare in the study. The first treatment period will be followed by an extension period during which the patients will receive the same treatment for any subsequent flares within 52 weeks of randomization. Each new flare treated will initiate a ...

Phase

0.0 miles

Learn More »

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

This study is conducted to evaluate the effects of UMEC 62.5 microgram (mcg) and UMEC 31.25 mcg on lung function versus placebo after 24 weeks of treatment. This study will provide important information regarding the efficacy and safety of UMEC when administered in a separate inhaler to subjects on a ...

Phase

0.0 miles

Learn More »

A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus

This is a Phase Ib, randomized, blinded, placebo-controlled, multiple ascending−dose study of the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of BFKB8488A in participants with Type 2 diabetes mellitus. A maximum of approximately 140 participants will be enrolled across multiple sites in the United States. Participants will be randomly ...

Phase

0.0 miles

Learn More »

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

The duration per patient is up to 85 weeks, including a Screening Period consisting of a Screening phase of up to 2 weeks and a 2-week single-blind Run-in phase, a 26-week double blind Core Treatment Period, a 53 week double blind Extension, and a 2-week post treatment Follow-up period to ...

Phase

0.0 miles

Learn More »

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

A multi-regional clinical trial with participating sites planned in the following countries pending approval from the applicable oversight authorities: - Argentina - Brazil - Bulgaria - Canada - Colombia - Czech Republic - Denmark - France - Germany - Hungary - India - Israel - Japan - Mexico - Netherlands ...

Phase

0.0 miles

Learn More »